nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—CYP1A2—Anagrelide—hematologic cancer	0.0412	0.0677	CbGbCtD
Dexmedetomidine—CYP1A1—Methoxsalen—hematologic cancer	0.0411	0.0677	CbGbCtD
Dexmedetomidine—CYP1A1—Bortezomib—hematologic cancer	0.0391	0.0644	CbGbCtD
Dexmedetomidine—CYP1A1—Daunorubicin—hematologic cancer	0.0374	0.0616	CbGbCtD
Dexmedetomidine—CYP1A1—Thalidomide—hematologic cancer	0.0341	0.0561	CbGbCtD
Dexmedetomidine—CYP1A1—Dacarbazine—hematologic cancer	0.0293	0.0482	CbGbCtD
Dexmedetomidine—CYP2E1—Thalidomide—hematologic cancer	0.0263	0.0433	CbGbCtD
Dexmedetomidine—CYP1A1—Dasatinib—hematologic cancer	0.023	0.0379	CbGbCtD
Dexmedetomidine—CYP2E1—Dacarbazine—hematologic cancer	0.0226	0.0373	CbGbCtD
Dexmedetomidine—CYP2D6—Lomustine—hematologic cancer	0.0218	0.0359	CbGbCtD
Dexmedetomidine—CYP1A2—Carmustine—hematologic cancer	0.0216	0.0356	CbGbCtD
Dexmedetomidine—CYP2D6—Idarubicin—hematologic cancer	0.0195	0.032	CbGbCtD
Dexmedetomidine—CYP1A2—Methoxsalen—hematologic cancer	0.0184	0.0302	CbGbCtD
Dexmedetomidine—CYP2E1—Mitoxantrone—hematologic cancer	0.0176	0.0289	CbGbCtD
Dexmedetomidine—CYP1A2—Bortezomib—hematologic cancer	0.0175	0.0288	CbGbCtD
Dexmedetomidine—CYP1A2—Daunorubicin—hematologic cancer	0.0167	0.0275	CbGbCtD
Dexmedetomidine—CYP2D6—Hydroxyurea—hematologic cancer	0.0166	0.0272	CbGbCtD
Dexmedetomidine—CYP1A2—Alitretinoin—hematologic cancer	0.0164	0.0269	CbGbCtD
Dexmedetomidine—CYP1A2—Thalidomide—hematologic cancer	0.0152	0.0251	CbGbCtD
Dexmedetomidine—CYP2D6—Bortezomib—hematologic cancer	0.0144	0.0237	CbGbCtD
Dexmedetomidine—CYP1A2—Dacarbazine—hematologic cancer	0.0131	0.0215	CbGbCtD
Dexmedetomidine—CYP1A2—Imatinib—hematologic cancer	0.0128	0.0211	CbGbCtD
Dexmedetomidine—CYP1A1—Dexamethasone—hematologic cancer	0.0118	0.0194	CbGbCtD
Dexmedetomidine—CYP2E1—Etoposide—hematologic cancer	0.0111	0.0182	CbGbCtD
Dexmedetomidine—CYP2D6—Imatinib—hematologic cancer	0.0106	0.0174	CbGbCtD
Dexmedetomidine—CYP1A2—Dasatinib—hematologic cancer	0.0103	0.0169	CbGbCtD
Dexmedetomidine—CYP2D6—Nilotinib—hematologic cancer	0.00959	0.0158	CbGbCtD
Dexmedetomidine—CYP2D6—Vinorelbine—hematologic cancer	0.00951	0.0156	CbGbCtD
Dexmedetomidine—CYP2E1—Dexamethasone—hematologic cancer	0.00911	0.015	CbGbCtD
Dexmedetomidine—CYP1A2—Etoposide—hematologic cancer	0.00641	0.0105	CbGbCtD
Dexmedetomidine—CYP2D6—Vinblastine—hematologic cancer	0.00586	0.00964	CbGbCtD
Dexmedetomidine—CYP2D6—Dexamethasone—hematologic cancer	0.00434	0.00714	CbGbCtD
Dexmedetomidine—CYP2D6—Doxorubicin—hematologic cancer	0.0036	0.00592	CbGbCtD
Dexmedetomidine—CYP1A2—hematopoietic system—hematologic cancer	5.73e-05	0.0554	CbGeAlD
Dexmedetomidine—SLC6A2—gonad—hematologic cancer	5.66e-05	0.0548	CbGeAlD
Dexmedetomidine—CYP1A1—hematopoietic system—hematologic cancer	5.65e-05	0.0546	CbGeAlD
Dexmedetomidine—ADRA2A—hematopoietic system—hematologic cancer	5.27e-05	0.0509	CbGeAlD
Dexmedetomidine—CYP2E1—hematopoietic system—hematologic cancer	5.15e-05	0.0498	CbGeAlD
Dexmedetomidine—Dermatitis—Thalidomide—hematologic cancer	4.48e-05	0.000148	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—hematologic cancer	4.47e-05	0.000148	CcSEcCtD
Dexmedetomidine—Dizziness—Alitretinoin—hematologic cancer	4.47e-05	0.000148	CcSEcCtD
Dexmedetomidine—Diarrhoea—Vincristine—hematologic cancer	4.46e-05	0.000148	CcSEcCtD
Dexmedetomidine—Headache—Thalidomide—hematologic cancer	4.45e-05	0.000148	CcSEcCtD
Dexmedetomidine—Pain—Prednisolone—hematologic cancer	4.45e-05	0.000148	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—hematologic cancer	4.45e-05	0.000148	CcSEcCtD
Dexmedetomidine—Dizziness—Ifosfamide—hematologic cancer	4.42e-05	0.000147	CcSEcCtD
Dexmedetomidine—ADRA2C—blood—hematologic cancer	4.37e-05	0.0423	CbGeAlD
Dexmedetomidine—Nausea—Thiotepa—hematologic cancer	4.37e-05	0.000145	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Etoposide—hematologic cancer	4.35e-05	0.000144	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—hematologic cancer	4.34e-05	0.000144	CcSEcCtD
Dexmedetomidine—Diarrhoea—Mitoxantrone—hematologic cancer	4.34e-05	0.000144	CcSEcCtD
Dexmedetomidine—Diarrhoea—Irinotecan—hematologic cancer	4.34e-05	0.000144	CcSEcCtD
Dexmedetomidine—Vomiting—Carmustine—hematologic cancer	4.34e-05	0.000144	CcSEcCtD
Dexmedetomidine—SLC6A2—lung—hematologic cancer	4.33e-05	0.0418	CbGeAlD
Dexmedetomidine—Pneumonia—Doxorubicin—hematologic cancer	4.32e-05	0.000143	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Etoposide—hematologic cancer	4.32e-05	0.000143	CcSEcCtD
Dexmedetomidine—Infection—Dexamethasone—hematologic cancer	4.32e-05	0.000143	CcSEcCtD
Dexmedetomidine—Infection—Betamethasone—hematologic cancer	4.32e-05	0.000143	CcSEcCtD
Dexmedetomidine—Dizziness—Vincristine—hematologic cancer	4.31e-05	0.000143	CcSEcCtD
Dexmedetomidine—Rash—Carmustine—hematologic cancer	4.3e-05	0.000143	CcSEcCtD
Dexmedetomidine—Dermatitis—Carmustine—hematologic cancer	4.3e-05	0.000143	CcSEcCtD
Dexmedetomidine—Vomiting—Alitretinoin—hematologic cancer	4.3e-05	0.000143	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Prednisolone—hematologic cancer	4.29e-05	0.000142	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—hematologic cancer	4.29e-05	0.000142	CcSEcCtD
Dexmedetomidine—Anaemia—Prednisone—hematologic cancer	4.29e-05	0.000142	CcSEcCtD
Dexmedetomidine—Headache—Carmustine—hematologic cancer	4.28e-05	0.000142	CcSEcCtD
Dexmedetomidine—Dyspnoea—Triamcinolone—hematologic cancer	4.27e-05	0.000142	CcSEcCtD
Dexmedetomidine—Rash—Alitretinoin—hematologic cancer	4.26e-05	0.000141	CcSEcCtD
Dexmedetomidine—Agitation—Prednisone—hematologic cancer	4.26e-05	0.000141	CcSEcCtD
Dexmedetomidine—Dermatitis—Alitretinoin—hematologic cancer	4.26e-05	0.000141	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Betamethasone—hematologic cancer	4.25e-05	0.000141	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Dexamethasone—hematologic cancer	4.25e-05	0.000141	CcSEcCtD
Dexmedetomidine—Vomiting—Ifosfamide—hematologic cancer	4.25e-05	0.000141	CcSEcCtD
Dexmedetomidine—Tachycardia—Betamethasone—hematologic cancer	4.24e-05	0.000141	CcSEcCtD
Dexmedetomidine—Tachycardia—Dexamethasone—hematologic cancer	4.24e-05	0.000141	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—hematologic cancer	4.24e-05	0.000141	CcSEcCtD
Dexmedetomidine—Headache—Alitretinoin—hematologic cancer	4.24e-05	0.00014	CcSEcCtD
Dexmedetomidine—Diarrhoea—Gemcitabine—hematologic cancer	4.23e-05	0.00014	CcSEcCtD
Dexmedetomidine—Nausea—Thalidomide—hematologic cancer	4.22e-05	0.00014	CcSEcCtD
Dexmedetomidine—Rash—Ifosfamide—hematologic cancer	4.21e-05	0.00014	CcSEcCtD
Dexmedetomidine—Dermatitis—Ifosfamide—hematologic cancer	4.21e-05	0.00014	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—hematologic cancer	4.21e-05	0.00014	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Dexamethasone—hematologic cancer	4.2e-05	0.000139	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Betamethasone—hematologic cancer	4.2e-05	0.000139	CcSEcCtD
Dexmedetomidine—Dizziness—Irinotecan—hematologic cancer	4.2e-05	0.000139	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—hematologic cancer	4.19e-05	0.000139	CcSEcCtD
Dexmedetomidine—Abdominal pain—Etoposide—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Dexmedetomidine—Body temperature increased—Etoposide—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—hematologic cancer	4.17e-05	0.000138	CcSEcCtD
Dexmedetomidine—Vomiting—Vincristine—hematologic cancer	4.14e-05	0.000137	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—hematologic cancer	4.13e-05	0.000137	CcSEcCtD
Dexmedetomidine—Rash—Vincristine—hematologic cancer	4.11e-05	0.000136	CcSEcCtD
Dexmedetomidine—Dermatitis—Vincristine—hematologic cancer	4.11e-05	0.000136	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—hematologic cancer	4.1e-05	0.000136	CcSEcCtD
Dexmedetomidine—Pain—Triamcinolone—hematologic cancer	4.09e-05	0.000136	CcSEcCtD
Dexmedetomidine—SLC6A2—testis—hematologic cancer	4.08e-05	0.0395	CbGeAlD
Dexmedetomidine—Headache—Vincristine—hematologic cancer	4.08e-05	0.000135	CcSEcCtD
Dexmedetomidine—CYP2D6—hematopoietic system—hematologic cancer	4.08e-05	0.0394	CbGeAlD
Dexmedetomidine—Hypotension—Dexamethasone—hematologic cancer	4.06e-05	0.000135	CcSEcCtD
Dexmedetomidine—Hypotension—Betamethasone—hematologic cancer	4.06e-05	0.000135	CcSEcCtD
Dexmedetomidine—Nausea—Carmustine—hematologic cancer	4.06e-05	0.000134	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—hematologic cancer	4.04e-05	0.000134	CcSEcCtD
Dexmedetomidine—Vomiting—Irinotecan—hematologic cancer	4.04e-05	0.000134	CcSEcCtD
Dexmedetomidine—Vomiting—Mitoxantrone—hematologic cancer	4.04e-05	0.000134	CcSEcCtD
Dexmedetomidine—Nausea—Alitretinoin—hematologic cancer	4.02e-05	0.000133	CcSEcCtD
Dexmedetomidine—Convulsion—Prednisone—hematologic cancer	4.02e-05	0.000133	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—hematologic cancer	4.01e-05	0.000133	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—hematologic cancer	4.01e-05	0.000133	CcSEcCtD
Dexmedetomidine—ADRA2A—gonad—hematologic cancer	4e-05	0.0387	CbGeAlD
Dexmedetomidine—Hypertension—Prednisone—hematologic cancer	4e-05	0.000133	CcSEcCtD
Dexmedetomidine—Rash—Mitoxantrone—hematologic cancer	4e-05	0.000133	CcSEcCtD
Dexmedetomidine—Rash—Irinotecan—hematologic cancer	4e-05	0.000133	CcSEcCtD
Dexmedetomidine—Dermatitis—Mitoxantrone—hematologic cancer	4e-05	0.000133	CcSEcCtD
Dexmedetomidine—Dermatitis—Irinotecan—hematologic cancer	4e-05	0.000133	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—hematologic cancer	3.99e-05	0.000132	CcSEcCtD
Dexmedetomidine—Headache—Mitoxantrone—hematologic cancer	3.98e-05	0.000132	CcSEcCtD
Dexmedetomidine—Headache—Irinotecan—hematologic cancer	3.98e-05	0.000132	CcSEcCtD
Dexmedetomidine—Nausea—Ifosfamide—hematologic cancer	3.97e-05	0.000132	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Triamcinolone—hematologic cancer	3.95e-05	0.000131	CcSEcCtD
Dexmedetomidine—Diarrhoea—Cisplatin—hematologic cancer	3.94e-05	0.000131	CcSEcCtD
Dexmedetomidine—Anxiety—Prednisone—hematologic cancer	3.93e-05	0.00013	CcSEcCtD
Dexmedetomidine—Vomiting—Gemcitabine—hematologic cancer	3.93e-05	0.00013	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—hematologic cancer	3.92e-05	0.00013	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—hematologic cancer	3.9e-05	0.000129	CcSEcCtD
Dexmedetomidine—Rash—Gemcitabine—hematologic cancer	3.9e-05	0.000129	CcSEcCtD
Dexmedetomidine—Dermatitis—Gemcitabine—hematologic cancer	3.89e-05	0.000129	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Dexmedetomidine—Headache—Gemcitabine—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Dexmedetomidine—Nausea—Vincristine—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—hematologic cancer	3.87e-05	0.000128	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—hematologic cancer	3.85e-05	0.000128	CcSEcCtD
Dexmedetomidine—ADRA2C—lung—hematologic cancer	3.83e-05	0.0371	CbGeAlD
Dexmedetomidine—Oedema peripheral—Doxorubicin—hematologic cancer	3.8e-05	0.000126	CcSEcCtD
Dexmedetomidine—CYP1A2—blood—hematologic cancer	3.79e-05	0.0367	CbGeAlD
Dexmedetomidine—Body temperature increased—Triamcinolone—hematologic cancer	3.79e-05	0.000126	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—hematologic cancer	3.78e-05	0.000125	CcSEcCtD
Dexmedetomidine—Nausea—Irinotecan—hematologic cancer	3.77e-05	0.000125	CcSEcCtD
Dexmedetomidine—Nausea—Mitoxantrone—hematologic cancer	3.77e-05	0.000125	CcSEcCtD
Dexmedetomidine—Infection—Prednisone—hematologic cancer	3.76e-05	0.000125	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—hematologic cancer	3.75e-05	0.000124	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.75e-05	0.000124	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.75e-05	0.000124	CcSEcCtD
Dexmedetomidine—CYP1A1—blood—hematologic cancer	3.74e-05	0.0362	CbGeAlD
Dexmedetomidine—Chills—Epirubicin—hematologic cancer	3.74e-05	0.000124	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—hematologic cancer	3.72e-05	0.000123	CcSEcCtD
Dexmedetomidine—Pain—Dexamethasone—hematologic cancer	3.72e-05	0.000123	CcSEcCtD
Dexmedetomidine—Pain—Betamethasone—hematologic cancer	3.72e-05	0.000123	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—hematologic cancer	3.71e-05	0.000123	CcSEcCtD
Dexmedetomidine—Tachycardia—Prednisone—hematologic cancer	3.69e-05	0.000122	CcSEcCtD
Dexmedetomidine—Nausea—Gemcitabine—hematologic cancer	3.67e-05	0.000122	CcSEcCtD
Dexmedetomidine—Vomiting—Cisplatin—hematologic cancer	3.66e-05	0.000121	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Prednisone—hematologic cancer	3.66e-05	0.000121	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—hematologic cancer	3.65e-05	0.000121	CcSEcCtD
Dexmedetomidine—Rash—Cisplatin—hematologic cancer	3.63e-05	0.00012	CcSEcCtD
Dexmedetomidine—Dermatitis—Cisplatin—hematologic cancer	3.63e-05	0.00012	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—hematologic cancer	3.63e-05	0.00012	CcSEcCtD
Dexmedetomidine—ADRA2C—testis—hematologic cancer	3.62e-05	0.035	CbGeAlD
Dexmedetomidine—Diarrhoea—Etoposide—hematologic cancer	3.61e-05	0.00012	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—hematologic cancer	3.58e-05	0.000119	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Betamethasone—hematologic cancer	3.58e-05	0.000119	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Dexamethasone—hematologic cancer	3.58e-05	0.000119	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—hematologic cancer	3.58e-05	0.000119	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Betamethasone—hematologic cancer	3.55e-05	0.000118	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.55e-05	0.000118	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—hematologic cancer	3.5e-05	0.000116	CcSEcCtD
Dexmedetomidine—Dizziness—Etoposide—hematologic cancer	3.49e-05	0.000116	CcSEcCtD
Dexmedetomidine—ADRA2A—blood—hematologic cancer	3.49e-05	0.0337	CbGeAlD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—hematologic cancer	3.47e-05	0.000115	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—hematologic cancer	3.46e-05	0.000115	CcSEcCtD
Dexmedetomidine—Dizziness—Prednisolone—hematologic cancer	3.44e-05	0.000114	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—hematologic cancer	3.44e-05	0.000114	CcSEcCtD
Dexmedetomidine—Abdominal pain—Betamethasone—hematologic cancer	3.43e-05	0.000114	CcSEcCtD
Dexmedetomidine—Abdominal pain—Dexamethasone—hematologic cancer	3.43e-05	0.000114	CcSEcCtD
Dexmedetomidine—Body temperature increased—Betamethasone—hematologic cancer	3.43e-05	0.000114	CcSEcCtD
Dexmedetomidine—Body temperature increased—Dexamethasone—hematologic cancer	3.43e-05	0.000114	CcSEcCtD
Dexmedetomidine—Nausea—Cisplatin—hematologic cancer	3.42e-05	0.000113	CcSEcCtD
Dexmedetomidine—CYP2E1—blood—hematologic cancer	3.41e-05	0.033	CbGeAlD
Dexmedetomidine—Mental disorder—Doxorubicin—hematologic cancer	3.38e-05	0.000112	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—hematologic cancer	3.36e-05	0.000111	CcSEcCtD
Dexmedetomidine—Vomiting—Etoposide—hematologic cancer	3.36e-05	0.000111	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—hematologic cancer	3.36e-05	0.000111	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—hematologic cancer	3.35e-05	0.000111	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—hematologic cancer	3.33e-05	0.00011	CcSEcCtD
Dexmedetomidine—Rash—Etoposide—hematologic cancer	3.33e-05	0.00011	CcSEcCtD
Dexmedetomidine—CYP1A2—lung—hematologic cancer	3.33e-05	0.0322	CbGeAlD
Dexmedetomidine—Dermatitis—Etoposide—hematologic cancer	3.33e-05	0.00011	CcSEcCtD
Dexmedetomidine—Headache—Etoposide—hematologic cancer	3.31e-05	0.00011	CcSEcCtD
Dexmedetomidine—Rash—Prednisolone—hematologic cancer	3.28e-05	0.000109	CcSEcCtD
Dexmedetomidine—CYP1A1—lung—hematologic cancer	3.28e-05	0.0317	CbGeAlD
Dexmedetomidine—Dermatitis—Prednisolone—hematologic cancer	3.28e-05	0.000109	CcSEcCtD
Dexmedetomidine—Headache—Prednisolone—hematologic cancer	3.26e-05	0.000108	CcSEcCtD
Dexmedetomidine—Constipation—Prednisone—hematologic cancer	3.24e-05	0.000107	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—hematologic cancer	3.19e-05	0.000106	CcSEcCtD
Dexmedetomidine—Dizziness—Triamcinolone—hematologic cancer	3.17e-05	0.000105	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—hematologic cancer	3.14e-05	0.000104	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—hematologic cancer	3.14e-05	0.000104	CcSEcCtD
Dexmedetomidine—Nausea—Etoposide—hematologic cancer	3.14e-05	0.000104	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—hematologic cancer	3.13e-05	0.000104	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Prednisone—hematologic cancer	3.12e-05	0.000103	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—hematologic cancer	3.1e-05	0.000103	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—hematologic cancer	3.1e-05	0.000103	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Prednisone—hematologic cancer	3.09e-05	0.000103	CcSEcCtD
Dexmedetomidine—Nausea—Prednisolone—hematologic cancer	3.09e-05	0.000103	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—hematologic cancer	3.08e-05	0.000102	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—hematologic cancer	3.08e-05	0.000102	CcSEcCtD
Dexmedetomidine—ADRA2A—lung—hematologic cancer	3.06e-05	0.0296	CbGeAlD
Dexmedetomidine—Hyperhidrosis—Methotrexate—hematologic cancer	3.06e-05	0.000101	CcSEcCtD
Dexmedetomidine—Vomiting—Triamcinolone—hematologic cancer	3.04e-05	0.000101	CcSEcCtD
Dexmedetomidine—Rash—Triamcinolone—hematologic cancer	3.02e-05	0.0001	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—hematologic cancer	3.02e-05	0.0001	CcSEcCtD
Dexmedetomidine—Dermatitis—Triamcinolone—hematologic cancer	3.02e-05	0.0001	CcSEcCtD
Dexmedetomidine—Headache—Triamcinolone—hematologic cancer	3e-05	9.95e-05	CcSEcCtD
Dexmedetomidine—CYP2E1—lung—hematologic cancer	2.99e-05	0.0289	CbGeAlD
Dexmedetomidine—Abdominal pain—Prednisone—hematologic cancer	2.99e-05	9.92e-05	CcSEcCtD
Dexmedetomidine—Body temperature increased—Prednisone—hematologic cancer	2.99e-05	9.92e-05	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—hematologic cancer	2.98e-05	9.89e-05	CcSEcCtD
Dexmedetomidine—Diarrhoea—Betamethasone—hematologic cancer	2.97e-05	9.86e-05	CcSEcCtD
Dexmedetomidine—Diarrhoea—Dexamethasone—hematologic cancer	2.97e-05	9.86e-05	CcSEcCtD
Dexmedetomidine—SLC6A2—lymph node—hematologic cancer	2.96e-05	0.0286	CbGeAlD
Dexmedetomidine—Hypotension—Methotrexate—hematologic cancer	2.95e-05	9.8e-05	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—hematologic cancer	2.94e-05	9.75e-05	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—hematologic cancer	2.91e-05	9.64e-05	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—hematologic cancer	2.9e-05	9.61e-05	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—hematologic cancer	2.9e-05	9.6e-05	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—hematologic cancer	2.89e-05	9.58e-05	CcSEcCtD
Dexmedetomidine—ADRA2A—testis—hematologic cancer	2.89e-05	0.0279	CbGeAlD
Dexmedetomidine—Dizziness—Dexamethasone—hematologic cancer	2.87e-05	9.53e-05	CcSEcCtD
Dexmedetomidine—Dizziness—Betamethasone—hematologic cancer	2.87e-05	9.53e-05	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—hematologic cancer	2.86e-05	9.49e-05	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—hematologic cancer	2.85e-05	9.44e-05	CcSEcCtD
Dexmedetomidine—Nausea—Triamcinolone—hematologic cancer	2.84e-05	9.43e-05	CcSEcCtD
Dexmedetomidine—CYP2E1—testis—hematologic cancer	2.82e-05	0.0273	CbGeAlD
Dexmedetomidine—Dyspnoea—Methotrexate—hematologic cancer	2.82e-05	9.35e-05	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—hematologic cancer	2.81e-05	9.32e-05	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—hematologic cancer	2.79e-05	9.26e-05	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—hematologic cancer	2.77e-05	9.17e-05	CcSEcCtD
Dexmedetomidine—Vomiting—Betamethasone—hematologic cancer	2.76e-05	9.16e-05	CcSEcCtD
Dexmedetomidine—Vomiting—Dexamethasone—hematologic cancer	2.76e-05	9.16e-05	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—hematologic cancer	2.76e-05	9.15e-05	CcSEcCtD
Dexmedetomidine—Rash—Betamethasone—hematologic cancer	2.74e-05	9.08e-05	CcSEcCtD
Dexmedetomidine—Rash—Dexamethasone—hematologic cancer	2.74e-05	9.08e-05	CcSEcCtD
Dexmedetomidine—Dermatitis—Dexamethasone—hematologic cancer	2.74e-05	9.08e-05	CcSEcCtD
Dexmedetomidine—Dermatitis—Betamethasone—hematologic cancer	2.74e-05	9.08e-05	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.73e-05	9.05e-05	CcSEcCtD
Dexmedetomidine—Headache—Betamethasone—hematologic cancer	2.72e-05	9.03e-05	CcSEcCtD
Dexmedetomidine—Headache—Dexamethasone—hematologic cancer	2.72e-05	9.03e-05	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—hematologic cancer	2.72e-05	9.02e-05	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—hematologic cancer	2.7e-05	8.97e-05	CcSEcCtD
Dexmedetomidine—CYP2D6—blood—hematologic cancer	2.7e-05	0.0261	CbGeAlD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—hematologic cancer	2.68e-05	8.89e-05	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—hematologic cancer	2.67e-05	8.86e-05	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—hematologic cancer	2.65e-05	8.78e-05	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—hematologic cancer	2.64e-05	8.75e-05	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—hematologic cancer	2.63e-05	8.72e-05	CcSEcCtD
Dexmedetomidine—ADRA2C—lymph node—hematologic cancer	2.62e-05	0.0254	CbGeAlD
Dexmedetomidine—Feeling abnormal—Methotrexate—hematologic cancer	2.61e-05	8.64e-05	CcSEcCtD
Dexmedetomidine—Diarrhoea—Prednisone—hematologic cancer	2.59e-05	8.58e-05	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—hematologic cancer	2.59e-05	8.57e-05	CcSEcCtD
Dexmedetomidine—Nausea—Betamethasone—hematologic cancer	2.58e-05	8.56e-05	CcSEcCtD
Dexmedetomidine—Nausea—Dexamethasone—hematologic cancer	2.58e-05	8.56e-05	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—hematologic cancer	2.56e-05	8.48e-05	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.55e-05	8.47e-05	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—hematologic cancer	2.53e-05	8.39e-05	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—hematologic cancer	2.53e-05	8.39e-05	CcSEcCtD
Dexmedetomidine—Dizziness—Prednisone—hematologic cancer	2.5e-05	8.3e-05	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—hematologic cancer	2.5e-05	8.29e-05	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—hematologic cancer	2.5e-05	8.29e-05	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—hematologic cancer	2.44e-05	8.09e-05	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—hematologic cancer	2.44e-05	8.09e-05	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—hematologic cancer	2.43e-05	8.07e-05	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—hematologic cancer	2.42e-05	8.02e-05	CcSEcCtD
Dexmedetomidine—Vomiting—Prednisone—hematologic cancer	2.41e-05	7.98e-05	CcSEcCtD
Dexmedetomidine—Rash—Prednisone—hematologic cancer	2.39e-05	7.91e-05	CcSEcCtD
Dexmedetomidine—Dermatitis—Prednisone—hematologic cancer	2.38e-05	7.9e-05	CcSEcCtD
Dexmedetomidine—Headache—Prednisone—hematologic cancer	2.37e-05	7.86e-05	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.36e-05	7.84e-05	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—hematologic cancer	2.34e-05	7.76e-05	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—hematologic cancer	2.34e-05	7.76e-05	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—hematologic cancer	2.34e-05	7.76e-05	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—hematologic cancer	2.34e-05	7.76e-05	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—hematologic cancer	2.26e-05	7.48e-05	CcSEcCtD
Dexmedetomidine—Nausea—Prednisone—hematologic cancer	2.25e-05	7.45e-05	CcSEcCtD
Dexmedetomidine—CYP1A1—lymph node—hematologic cancer	2.24e-05	0.0217	CbGeAlD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.24e-05	7.42e-05	CcSEcCtD
Dexmedetomidine—CYP2D6—testis—hematologic cancer	2.24e-05	0.0216	CbGeAlD
Dexmedetomidine—Abdominal pain—Doxorubicin—hematologic cancer	2.16e-05	7.18e-05	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—hematologic cancer	2.16e-05	7.18e-05	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—hematologic cancer	2.16e-05	7.17e-05	CcSEcCtD
Dexmedetomidine—ADRA2A—lymph node—hematologic cancer	2.09e-05	0.0202	CbGeAlD
Dexmedetomidine—Dizziness—Methotrexate—hematologic cancer	2.09e-05	6.93e-05	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—hematologic cancer	2.02e-05	6.71e-05	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—hematologic cancer	2.01e-05	6.67e-05	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—hematologic cancer	1.99e-05	6.61e-05	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—hematologic cancer	1.99e-05	6.61e-05	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—hematologic cancer	1.98e-05	6.57e-05	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—hematologic cancer	1.96e-05	6.49e-05	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—hematologic cancer	1.88e-05	6.24e-05	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—hematologic cancer	1.88e-05	6.23e-05	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—hematologic cancer	1.87e-05	6.21e-05	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—hematologic cancer	1.87e-05	6.19e-05	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—hematologic cancer	1.86e-05	6.18e-05	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—hematologic cancer	1.85e-05	6.15e-05	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—hematologic cancer	1.81e-05	6e-05	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—hematologic cancer	1.76e-05	5.83e-05	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—hematologic cancer	1.74e-05	5.77e-05	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—hematologic cancer	1.73e-05	5.72e-05	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—hematologic cancer	1.72e-05	5.72e-05	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—hematologic cancer	1.72e-05	5.69e-05	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—hematologic cancer	1.63e-05	5.39e-05	CcSEcCtD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAP2K1—hematologic cancer	4.4e-06	4.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGFR3—hematologic cancer	4.4e-06	4.92e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.39e-06	4.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CD—hematologic cancer	4.37e-06	4.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.37e-06	4.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK14—hematologic cancer	4.36e-06	4.87e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAP2K1—hematologic cancer	4.33e-06	4.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—PIK3CA—hematologic cancer	4.33e-06	4.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—hematologic cancer	4.32e-06	4.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CD—hematologic cancer	4.31e-06	4.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	4.3e-06	4.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—hematologic cancer	4.28e-06	4.79e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—hematologic cancer	4.28e-06	4.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—PIK3CA—hematologic cancer	4.26e-06	4.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CD—hematologic cancer	4.25e-06	4.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1B—hematologic cancer	4.24e-06	4.74e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.24e-06	4.74e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.24e-06	4.74e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FN1—hematologic cancer	4.22e-06	4.72e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—hematologic cancer	4.21e-06	4.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	4.21e-06	4.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—AKT1—hematologic cancer	4.2e-06	4.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	4.2e-06	4.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ALB—hematologic cancer	4.19e-06	4.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGF2—hematologic cancer	4.19e-06	4.68e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CG—hematologic cancer	4.18e-06	4.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BAD—hematologic cancer	4.17e-06	4.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NFKBIA—hematologic cancer	4.17e-06	4.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CASP3—hematologic cancer	4.16e-06	4.65e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—hematologic cancer	4.15e-06	4.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NOTCH1—hematologic cancer	4.13e-06	4.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL6—hematologic cancer	4.13e-06	4.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3R1—hematologic cancer	4.13e-06	4.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGF2—hematologic cancer	4.12e-06	4.61e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CREBBP—hematologic cancer	4.12e-06	4.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	4.08e-06	4.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	4.08e-06	4.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3R1—hematologic cancer	4.07e-06	4.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CD80—hematologic cancer	4.05e-06	4.53e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—hematologic cancer	4.05e-06	4.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	4.04e-06	4.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KIT—hematologic cancer	4.04e-06	4.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	4.04e-06	4.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—JUN—hematologic cancer	4.04e-06	4.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JAK2—hematologic cancer	4.01e-06	4.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3R1—hematologic cancer	4.01e-06	4.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	3.97e-06	4.44e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.97e-06	4.43e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JAK2—hematologic cancer	3.95e-06	4.42e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—hematologic cancer	3.94e-06	4.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—PIK3CA—hematologic cancer	3.93e-06	4.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MDM2—hematologic cancer	3.92e-06	4.38e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—hematologic cancer	3.92e-06	4.38e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—hematologic cancer	3.91e-06	4.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—hematologic cancer	3.91e-06	4.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CD—hematologic cancer	3.9e-06	4.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	3.9e-06	4.36e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CREBBP—hematologic cancer	3.88e-06	4.34e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—PIK3CA—hematologic cancer	3.87e-06	4.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	3.87e-06	4.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MDM2—hematologic cancer	3.86e-06	4.31e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ALB—hematologic cancer	3.85e-06	4.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	3.85e-06	4.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	3.83e-06	4.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK8—hematologic cancer	3.82e-06	4.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CB—hematologic cancer	3.81e-06	4.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MTOR—hematologic cancer	3.81e-06	4.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—AKT1—hematologic cancer	3.81e-06	4.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	3.8e-06	4.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	3.79e-06	4.23e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.78e-06	4.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	3.76e-06	4.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—EP300—hematologic cancer	3.76e-06	4.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	3.75e-06	4.2e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	3.75e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MTOR—hematologic cancer	3.75e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CB—hematologic cancer	3.75e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—hematologic cancer	3.75e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—hematologic cancer	3.75e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	3.75e-06	4.19e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	3.73e-06	4.17e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EP300—hematologic cancer	3.73e-06	4.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CB—hematologic cancer	3.7e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ABCB1—hematologic cancer	3.7e-06	4.14e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3R1—hematologic cancer	3.68e-06	4.12e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CD—hematologic cancer	3.68e-06	4.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	3.65e-06	4.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—JUN—hematologic cancer	3.65e-06	4.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—hematologic cancer	3.64e-06	4.07e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ALB—hematologic cancer	3.63e-06	4.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SRC—hematologic cancer	3.62e-06	4.05e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NCOR1—hematologic cancer	3.59e-06	4.02e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—hematologic cancer	3.59e-06	4.02e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—hematologic cancer	3.58e-06	4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1B—hematologic cancer	3.58e-06	4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	3.58e-06	4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	3.55e-06	3.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—AKT1—hematologic cancer	3.54e-06	3.96e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	3.54e-06	3.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—VEGFA—hematologic cancer	3.53e-06	3.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	3.53e-06	3.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1B—hematologic cancer	3.52e-06	3.94e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.52e-06	3.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CASP3—hematologic cancer	3.51e-06	3.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—hematologic cancer	3.5e-06	3.91e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—STAT3—hematologic cancer	3.49e-06	3.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—NRAS—hematologic cancer	3.49e-06	3.9e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL6—hematologic cancer	3.48e-06	3.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—AKT1—hematologic cancer	3.48e-06	3.89e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	3.48e-06	3.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3R1—hematologic cancer	3.47e-06	3.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CASP3—hematologic cancer	3.45e-06	3.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	3.45e-06	3.86e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—hematologic cancer	3.45e-06	3.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	3.44e-06	3.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL6—hematologic cancer	3.43e-06	3.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—hematologic cancer	3.41e-06	3.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—JUN—hematologic cancer	3.41e-06	3.81e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	3.4e-06	3.8e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CB—hematologic cancer	3.4e-06	3.8e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EP300—hematologic cancer	3.36e-06	3.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—hematologic cancer	3.36e-06	3.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	3.36e-06	3.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—JUN—hematologic cancer	3.35e-06	3.75e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MAPK3—hematologic cancer	3.34e-06	3.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—hematologic cancer	3.3e-06	3.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—hematologic cancer	3.29e-06	3.68e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SRC—hematologic cancer	3.27e-06	3.66e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	3.26e-06	3.64e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—hematologic cancer	3.25e-06	3.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—hematologic cancer	3.25e-06	3.63e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	3.24e-06	3.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	3.24e-06	3.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	3.22e-06	3.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	3.21e-06	3.59e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CB—hematologic cancer	3.21e-06	3.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—hematologic cancer	3.2e-06	3.58e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	3.2e-06	3.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	3.19e-06	3.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	3.18e-06	3.56e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—hematologic cancer	3.18e-06	3.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	3.17e-06	3.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	3.16e-06	3.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	3.15e-06	3.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.15e-06	3.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	3.15e-06	3.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EP300—hematologic cancer	3.14e-06	3.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	3.1e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	3.1e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EP300—hematologic cancer	3.09e-06	3.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SRC—hematologic cancer	3.06e-06	3.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—EP300—hematologic cancer	3.05e-06	3.41e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	3.01e-06	3.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SRC—hematologic cancer	3.01e-06	3.36e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	3e-06	3.35e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	2.98e-06	3.33e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.96e-06	3.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	2.95e-06	3.29e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	2.94e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—hematologic cancer	2.94e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—hematologic cancer	2.93e-06	3.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	2.93e-06	3.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	2.92e-06	3.27e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.92e-06	3.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.91e-06	3.25e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	2.9e-06	3.24e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	2.89e-06	3.23e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	2.87e-06	3.21e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	2.85e-06	3.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—hematologic cancer	2.84e-06	3.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	2.83e-06	3.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	2.82e-06	3.15e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—EP300—hematologic cancer	2.8e-06	3.13e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.8e-06	3.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PIK3CA—hematologic cancer	2.78e-06	3.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	2.77e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—hematologic cancer	2.77e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	2.77e-06	3.1e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.77e-06	3.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JUN—hematologic cancer	2.77e-06	3.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	2.76e-06	3.08e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—hematologic cancer	2.74e-06	3.06e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ALB—hematologic cancer	2.73e-06	3.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	2.73e-06	3.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	2.71e-06	3.03e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—hematologic cancer	2.69e-06	3.01e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	2.69e-06	3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	2.68e-06	3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	2.68e-06	2.99e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CG—hematologic cancer	2.67e-06	2.98e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—hematologic cancer	2.67e-06	2.98e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—EP300—hematologic cancer	2.64e-06	2.95e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	2.62e-06	2.93e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.61e-06	2.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	2.61e-06	2.92e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EP300—hematologic cancer	2.55e-06	2.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	2.55e-06	2.85e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	2.53e-06	2.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.49e-06	2.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	2.49e-06	2.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SRC—hematologic cancer	2.48e-06	2.77e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CREBBP—hematologic cancer	2.47e-06	2.76e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL6—hematologic cancer	2.44e-06	2.73e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	2.42e-06	2.7e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.41e-06	2.7e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—hematologic cancer	2.41e-06	2.69e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	2.39e-06	2.67e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	2.39e-06	2.67e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CD—hematologic cancer	2.35e-06	2.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	2.32e-06	2.6e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ALB—hematologic cancer	2.32e-06	2.59e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	2.3e-06	2.57e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.29e-06	2.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	2.29e-06	2.56e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—AKT1—hematologic cancer	2.27e-06	2.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PIK3CA—hematologic cancer	2.26e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	2.25e-06	2.52e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—hematologic cancer	2.25e-06	2.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—hematologic cancer	2.22e-06	2.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	2.22e-06	2.48e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3R1—hematologic cancer	2.21e-06	2.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.21e-06	2.47e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL6—hematologic cancer	2.2e-06	2.46e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	2.15e-06	2.4e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	2.12e-06	2.37e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—hematologic cancer	2.09e-06	2.33e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PIK3CA—hematologic cancer	2.07e-06	2.32e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL6—hematologic cancer	2.06e-06	2.3e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	2.05e-06	2.3e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CB—hematologic cancer	2.04e-06	2.28e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	2.03e-06	2.27e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL6—hematologic cancer	2.03e-06	2.26e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—EP300—hematologic cancer	1.99e-06	2.22e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PIK3CA—hematologic cancer	1.95e-06	2.18e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.9e-06	2.12e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.89e-06	2.11e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	1.87e-06	2.09e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—AKT1—hematologic cancer	1.84e-06	2.06e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.83e-06	2.04e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—hematologic cancer	1.77e-06	1.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.75e-06	1.95e-05	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—AKT1—hematologic cancer	1.69e-06	1.89e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—EP300—hematologic cancer	1.68e-06	1.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.67e-06	1.87e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—AKT1—hematologic cancer	1.6e-06	1.78e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.54e-06	1.72e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.47e-06	1.64e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PIK3CA—hematologic cancer	1.25e-06	1.39e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.2e-06	1.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—AKT1—hematologic cancer	1.02e-06	1.14e-05	CbGpPWpGaD
